HejuruUbuyobozi bukurikira
FDA Amabwiriza yibikoresho byubuvuzi bya AI
Inganda
UMUYOBOZI W'umuryango
An FDA predetermined change control plan (PCCP) describes specified planned modifications to a medical device, how the manufacturer will develop and validate them, and how their effects will be assessed.
Umva iki gitaboAI-byavuzwe · ~3 min
FDA reviews an AI-device PCCP as part of a marketing submission. The plan can support defined future changes without a separate submission for each change, within its authorized scope.
A PCCP is a planned change-management component of a medical-device marketing submission. FDA’s August 2025 final guidance gives recommendations for PCCPs tailored to AI-enabled device software functions, including the device constituent part of device-led combination products reviewed through 510(k), De Novo, and PMA pathways. FDA reviews the proposed plan with the marketing submission to assess whether the described changes can be made while maintaining a reasonable assurance of safety and effectiveness. A PCCP does not permit unrestricted changes. The guidance organizes the plan around three elements: a description of planned modifications, a modification protocol for developing, validating, and implementing those changes, and an impact assessment addressing benefits and risks. The planned changes need defined boundaries. The protocol should state methods, acceptance criteria, data controls, validation, implementation safeguards, and monitoring appropriate to the device and proposed change. The impact assessment should explain how changes could affect safety and effectiveness, including interactions among modifications. Vague promises to “retrain as needed” do not provide a meaningful boundary or evidence plan. After FDA authorizes a PCCP, a manufacturer may implement modifications that conform to the authorized plan without a new marketing submission for each described modification. It must still follow applicable quality-system, labeling, reporting, and other regulatory obligations. A proposed change outside the PCCP, or one that fails its protocol, requires a separate regulatory assessment. Depending on the change and device pathway, a new 510(k), De Novo, PMA supplement, or other action may be required. PCCP authorization therefore changes the route for a bounded category of updates; it does not exempt a product from device regulation. The 2025 guidance is final agency guidance and expresses FDA’s current recommendations; guidance does not itself establish legally enforceable responsibilities unless specific statutory or regulatory requirements apply. Manufacturers should distinguish this AI-focused guidance from earlier draft documents and from joint international PCCP guiding principles. Align scope, evidence, risk controls, and monitoring with the device and patient context.
A radiology software maker proposes a bounded retraining method, validation protocol, and performance limits for a device intended to detect a defined finding.
A manufacturer specifies which input hardware can be added and how each configuration will be tested before release.
A change to a model’s intended population falls outside the authorized PCCP, so the manufacturer evaluates whether a new marketing submission is required.
A quality team links each released model update to the authorized plan, validation evidence, risk review, and post-market monitoring record.
FDA’s guidance supports iterative improvement under defined controls while retaining review of safety and effectiveness. As experience accumulates, agency recommendations, standards, and accepted evidence methods may evolve. Manufacturers should check the current FDA guidance and submission requirements when preparing a plan, and reassess when the device, intended population, or update method changes. A successful PCCP depends on evidence and operational controls after clearance as well as the initial submission. Schedule a review when FDA revises the guidance or the device’s update method changes.
Ibaruwa y'amakuru y'ubuntu
Inkuru eshatu zizewe za AI buri gitondo cy'iminsi y'akazi, zanditse mu rurimi rworoshye. Ubuntu iteka ryose, nta kwamamaza.
Imeri imwe buri munsi y'akazi. Kwiyimura mu buryo bumwe. Ntitwigera tugurisha cyangwa ngo dusangire aderesi yawe.
Isuzume
Ibisubizo ako kanya kuri buri kibazo, n'icyemezo gishobora gusangirwa gifite ID yagenzurwa umaze gutsinda isomo.
Fasha uburezi bwa AI bw'ubuntu. AI Understanding ni umuryango utegamiye kuri leta wa 501(c)(3) — nta kwamamaza, nta kwishyura, iteka ryose. Tanga impano
An FDA predetermined change control plan (PCCP) describes specified planned modifications to a medical device, how the manufacturer will develop and validate them, and how their effects will be assessed. FDA reviews an AI-device PCCP as part of a marketing submission. The plan can support defined future changes without a separate submission for each change, within its authorized scope.
Ubuyobozi bwa nyuma bwa FDA busobanura ibyahinduwe, protocole yo kubishyira mubikorwa, no gusuzuma ingaruka zabyo.
FDA isubiramo PCCP nkigice cyo gutanga ibicuruzwa bijyanye.
Gahunda irashobora gushyigikira ibyahinduwe ejo hazaza hatabayeho gutanga ibicuruzwa bishya kuri buri mpinduka, niba bakurikiza gahunda yemewe.
Impinduka hanze yurwego rwemewe ikeneye isuzumabumenyi kandi irashobora gusaba koherezwa.
FDA igaragaza ubuyobozi bwayo bwa nyuma nkuko byatanzwe muri Kanama 2025.
Komeza wige
Abandi bayobozi batoranijwe kuriyi ngingo
HejuruUbuyobozi bukurikira
FDA Amabwiriza yibikoresho byubuvuzi bya AI
Inganda